Navigation Links
Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer
Date:2/6/2008

Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.

The clinical trial is part of a $9 million grant from the National Cancer Institute (NCI) awarded to Henry Ford to study the effectiveness of gene therapy to treat prostate cancer.

As part of this research grant we have had encouraging results involving two smaller clinical studies, says Svend Freytag, Ph.D., division head of Research, Radiation Oncology, Henry Ford Hospital.

Dr. Freytag, along with Benjamin Movsas, M.D., chair of Radiation Oncology and Hans Stricker, M.D., vice chair of Urology at Henry Ford Hospital are the studys key researchers.

Because of the results from the previous trials, NCI approved a phase III trial involving 280 prostate cancer patients over a three-year period. A phase III trial is the final stage in a study to determine if the treatment being studied should become the standard treatment.

Currently radiation therapy (without the gene therapy) or surgical removal of the prostate is the standard treatment for patients with localized prostate cancer, with similar cure rates. Prostate Cancer is the second leading cause of cancer death for men according to the American Cancer Society.

When you consider that across the world most trials involving gene therapy are in very early stages of development involving research in test tubes, the fact that Henry Ford Hospital is now embarking on a major phase III clinical trial to test this as a new standard treatment, is a testament to the world class innovative research taking place right here, says Dr. Movsas, principal investigator of the study. To my knowledge, this is the only place in the world where such a gene therapy study is available for this group of patients, he adds.

The first FDA-approved clinical trial studied approximately 15 men who previously had radiation therapy alone and experienced cancer regrowth. They were given only the suicide gene therapy, which was proven safe. Suicide gene therapy uses two specific genes, encased in a virus (the one associated with the common cold), to convert non-toxic drugs into highly toxic agents when the genes are inserted into a tumor. The genes activate chemotherapeutic agents locally to destroy the cancer cells and make them more sensitive to enhance the effectiveness of radiation therapy.

In this setting gene therapy didnt eliminate the cancer, but it did slow its rate of growth and delayed by an average of 2.5 years, when the patients began hormone therapy. Since hormone therapy can be associated with many side effects, delaying the therapy can improve a patients quality of life.

The second trial of about 25 men with newly diagnosed prostate cancer combined the suicide gene therapy with radiation therapy. Again, it proved safe and demonstrated a benefit in a certain class of patients. Researchers found that all of the patients with intermediate-risk prostate cancer (the group eligible for this study) had excellent responses following the combined treatment, with no evidence of cancer regrowth to date.

The main criteria for the phase III study requires either a patients PSA to be in the range of 10-20 and/or a Gleason score of 7 (moderately differentiated tumor cells on the prostate biopsy).

In this randomized study, half of the patients will received the standard treatment for intermediate prostate cancer involving Intensity Modulated Radiation Therapy (IMRT), a high-precision radiation therapy technique uses computer-controlled x-ray beams so that the radiation delivery conforms to the shape of the tumor.

The other half will receive the combination treatment involving the gene therapy with IMRT to see which treatment is most effective.


'/>"/>

Contact: Zoila Brown
zbrown1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Henry Schein Medical Systems MicroMD(R) EMR 5.0
2. AAPD to Present 2008 Henry B. Betts Award to International Human Rights Disability Advocate Eric Rosenthal
3. Michigan Quality Council (MQC) Names Henry Ford Health System 2007 State Quality Award Recipient
4. Repligen Elects Earl Henry, M.D. to the Board of Directors
5. Program for Stroke Survivors and Friends Hosted by Henry Ford Hospital
6. Fund-Raiser for Henry Ford Hospitals Stroke Program
7. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
8. Grosse Pointes Cottage Hospital Joins Henry Ford Health System
9. New Rhode Island Hospital study shows inadequate diagnostic criteria for eating disorders
10. IPC The Hospitalist Company, Inc. Announces Closing of IPO and Exercise of Underwriters Over-Allotment Option
11. Jacobs Receives Contract from Catholic Healthcare West to Assist Sequoia Hospital Expansion Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Today American University of Antigua (AUA) ... announced the AUA-FIU Global MD Program. Students in the Global MD Program ... a Certificate of Completion from the FIU Herbert Wertheim College of Medicine Clinical ...
(Date:5/25/2016)... ... May 25, 2016 , ... CloudLIMS, joins an elite number of companies ... Solution Providers list of 2016 by CIOReview. , In a deliberate session with the ... Solution Providers 2016 has been concluded with. The positioning is based on evaluation of ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Cheryl Bowker of ... to bestow: the Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s ... which continues to inspire all those who knew him. The award named for him ...
(Date:5/25/2016)... ... 2016 , ... Afrimesure specializes in providing clients with ideal ... and HVAC facilities. Their knowledgeable staff also takes care of the installation, IQ/OQ/PQ ... offers a variety of MadgeTech systems available for sterilization and temperature monitoring, including ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... results of its annual Medical and Prescription Drug survey , an ... , The survey, which was conducted in December 2015, indicates that employers are ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Cirujanos holandeses ... ayudar a los médicos a compartir sus mejores prácticas ... escala mundial. Profesionales médicos de Europa, África, ... apuntado a la aplicación, que combina la transmisión en ... totalmente seguro. Educación   "Imagine un ...
(Date:5/24/2016)...   , Study met both ... in , Excellent plus Good ... of the ascending colon   ,      ... announced new positive data from the phase III MORA study for ... litre PEG with ascorbate. The study met both primary endpoints showing ...
(Date:5/24/2016)... May 24, 2016 ARANZ Medical ... the healthcare sector, has been named the Coretex Hi-Tech Emerging ... 2016. Dr Bruce Davey , CEO of ... team.  It,s really good to be recognised for the work ... products are used in 35 countries around the world from ...
Breaking Medicine Technology: